Icon

BRAFTOVI (nda210496)- (50MG,75MG)

ENCORAFENIB ARRAY BIOPHARMA INC
50MG,75MG
Yes No
2032-Nov-21 2023-Jun-27
None None
None No
BRAFTOVI is a kinase inhibitor indicated:  in combination with binimetinib, for the treatment of p atients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.  in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
0 2 0
Total Other Developers 3
Drugs with Suitability No
50MG ** ** - - -
75MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.